湖北共同药业股份有限公司 | 证券代码：300966 | 证券简称：共同药业 公告编号：2024-029 | | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | 董事会认为：本次公司为控股子公司湖北华海共同药业有限公司（以下简称"华 海共同"）提供担保有助于解决其业务发展中的资金需求问题，对公司业务扩展起到积 极作用。本次被担保对象为公司合并报表范围内的控股子公司，公司对华海共同日常经 营有绝对控制权，在担保期限内公司有能力对其经营管理风险进行有效控制，控股子公 司华海共同其他股东浙江华海药业股份有限公司按出资比例 46.9167%提供同等担 保。 综上，本次担保事项风险可控，不存在损害公司及全体股东利益的情形。本次 对外担保符合有关法律法规和《公司章程》的规定，决策程序合规有效，不存在损 害公司和中小股东利益的情形。 第二届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"或"共同药业"）第二届董事 会第二十三次会议于 2024 年 ...

2024 年 04 月 26 日 公司点评 增持/维持 | --- | --- | --- | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

合并资产负债表 | 编制单位：湖北共同药业股份有限公司 | | 2024 年 3 月 31 日 | 单位：人民币元 | | --- | --- | --- | --- | | | 项 目 | 2024 年 3 月 31 日 | 2024 年 1 月 1 日 | | 流动资产： | | | | | 货币资金 | | 116,793,029.53 | 181,973,811.45 | | 交易性金融资产 | | 1,010.50 | 1,010.45 | | 衍生金融资产 | | | | | 应收票据 | | 6,250,022.23 | 9,502,405.17 | | 应收账款 | | 212,376,065.94 | 210,199,485.52 | | 应收款项融资 | | 9,205,533.64 | 15,694,632.58 | | 预付款项 | | 28,118,132.65 | 19,796,737.00 | | 其他应收款 | | 2,493,662.88 | 2,146,241.55 | | 其中：应收利息 | | | | | 应收股利 | | | | | 存货 | | 370,732,97 ...

湖北共同药业股份有限公司 2023 年度监事会工作报告 2023 年，湖北共同药业股份有限公司（以下简称"公司"）监事会根据《公司 法》《证券法》《深圳证券交易所创业板股票上市规则》以及《公司章程》和《监 事会议事规则》的规定，本着对公司全体股东负责的精神，认真履行职责。监事会 对 2023 年公司生产经营情况、财务状况、内部管理制度和公司董事、高级管理人员 履行职责的情况进行监督，切实维护了公司及股东的合法权益。现将 2023 年监事会 主要工作情况汇报如下： 一、2023 年监事会召开会议情况 2023 年，公司监事会共召开了 7 次会议，会议的召开符合《公司法》《公司章 程》和《监事会议事规则》的有关规定，全体监事均出席了会议。2023 年，监事会 召开会议情况如下： | 会议届次 | | 召开时间 | | | | 审议议案 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 1.《关于<湖北共同药业股份有限公司 2023 年限制性股票激励计 | | | | | | | | 划（草案）>及其摘要的议案》 | | 第二届监事会 | 202 ...

Financial Performance - The company's operating revenue for 2023 was ¥566,399,208.58, a decrease of 6.31% compared to ¥604,571,473.19 in 2022[20]. - The net profit attributable to shareholders for 2023 was ¥23,005,014.76, down 42.78% from ¥40,187,745.00 in 2022[20]. - The net profit after deducting non-recurring gains and losses was ¥20,961,686.55, a decline of 44.07% from ¥36,738,609.57 in 2022[20]. - The net cash flow from operating activities improved significantly to ¥68,132,540.93, compared to a negative cash flow of ¥24,036,809.43 in 2022, representing a 383.45% increase[20]. - Total assets at the end of 2023 reached ¥2,447,740,699.18, an increase of 18.29% from ¥2,068,317,317.70 at the end of 2022[20]. - The net assets attributable to shareholders increased by 2.66% to ¥952,749,525.16 from ¥928,070,078.38 in 2022[20]. - The basic earnings per share for 2023 was ¥0.20, down 42.86% from ¥0.35 in 2022[20]. - The company reported a significant increase in cash flow from operations in the fourth quarter, amounting to ¥58,729,315.44[22]. - The company received government subsidies amounting to ¥4,325,857.42 in 2023, slightly down from ¥4,335,187.31 in 2022[25]. - The total operating revenue for 2023 was ¥566,399,208.58, a decrease of 6.31% compared to ¥604,571,473.19 in 2022[58]. - The revenue from self-produced products was ¥394,888,218.52, accounting for 69.72% of total revenue, down 10.62% from ¥441,797,009.10 in 2022[58]. - The revenue from non-self-produced products increased by 5.37% to ¥171,510,990.06, representing 30.28% of total revenue[58]. - Domestic sales accounted for 77.25% of total revenue at ¥437,531,148.80, a decline of 13.65% from ¥506,665,962.05 in 2022[59]. - International sales rose by 31.62% to ¥128,868,059.78, increasing its share to 22.75% of total revenue[59]. - The gross profit margin for the steroid drug raw material manufacturing sector was 22.09%, a decrease of 0.77% from the previous year[60]. Company Operations - The company operates several subsidiaries, including Hubei Goto Biopharm Co., Ltd. and Hubei Goto Health Industry Co., Ltd., which may contribute to its overall market strategy[12]. - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of steroid drug raw materials[30]. - The company has an annual production capacity of 2,700 tons and offers over 100 types of steroid drug raw materials and intermediates[35]. - The company is the largest supplier of steroid drug starting materials in China and the only one covering the entire industrial chain of steroid hormones[34]. - The company has developed four leading technologies in steroid drug production, including strain direction, enzyme modification, steroid conversion, and green synthesis[35]. - The company’s subsidiary, Huahai Gongtong, is set to become the first domestic supplier to cover steroid hormone, progestogen, and corticosteroid raw materials simultaneously[34]. - The company has established long-term stable relationships with upstream suppliers, ensuring a smooth supply chain for raw materials[39]. - The company has adopted a flexible production model for customized or small-batch products, responding to customer orders effectively[40]. - The company is actively developing new products and production processes to meet the growing demands of its customers[41]. - The company has accelerated the construction of its raw material drug factory, with the first phase of product construction nearly completed, and has added a second phase production line to enhance its product offerings[48]. Research and Development - The company has increased R&D investment to drive innovation and product line expansion, aligning with its strategy of innovation-driven development[43]. - The company completed two batches of pilot tests for the GXRD0002 project, aiming to establish a stable production process for estriol raw materials, which is expected to significantly increase revenue[69]. - The company has achieved technical transfer for the GXRD0003 project, preparing to submit supplementary application materials for international certification, which will enhance its product pipeline and solidify its market position[69]. - Research and development investment for 2023 amounted to ¥38,098,898.41, representing 6.73% of operating revenue, a decrease from 7.47% in 2022[71]. - The number of R&D personnel increased by 5.88% to 126 in 2023, while the proportion of R&D personnel to total staff decreased from 22.16% in 2022 to 19.97%[71]. - The company has completed the technical transfer for multiple steroid hormone projects, which are expected to expand the product line and increase marketing reach, leading to a significant rise in revenue[69]. - The company is optimizing enzyme fermentation processes to enhance product quality and yield, with a target of achieving over 80% conversion rates in its production processes[70]. - The company has made significant progress in developing new products through biological pathways, which is expected to enhance its competitive advantage in both domestic and international markets[70]. - The company has successfully completed pilot tests for several key intermediate products, which will contribute to the expansion of its product line and improve overall product quality[70]. Corporate Governance - The company has a dedicated board secretary and securities representative to handle investor relations and communications[17]. - The company has established a performance evaluation and incentive mechanism linking the income of senior management to the company's operational performance[105]. - The company operates independently from its controlling shareholder, with a complete business system and independent operational capabilities[107]. - The company has a dedicated financial department with an independent accounting system and does not share bank accounts with its controlling shareholder[108]. - The company has three independent directors among its seven board members, ensuring governance diversity[112]. - The company’s independent directors have extensive backgrounds in law and finance, enhancing its governance structure[114][115]. - The company has a structured approach to remuneration, with decisions made by the board of directors and shareholders[119]. - The total remuneration for directors, supervisors, and senior management in 2023 amounted to 308.04 million CNY[120]. - The highest remuneration was received by the chairman and general manager, Xi Zuobin, totaling 72.93 million CNY[120]. Environmental Compliance - The company has a valid pollutant discharge permit effective until December 29, 2025, ensuring compliance with environmental regulations[141]. - The company reported a volatile organic compound emission concentration of 4.19 mg/L, well below the standard limit of 60 mg/L[141]. - The chemical oxygen demand in wastewater was reported at 122.5 mg/L, exceeding the standard limit of 40 mg/L, but no external discharge occurred[141]. - The ammonia nitrogen concentration in wastewater was 12.3 mg/L, significantly below the standard limit of 500 mg/L, with no external discharge[141]. - The company has adhered to multiple environmental protection laws and standards, ensuring regulatory compliance[141]. - The company has implemented a gas treatment process involving alkaline spraying, water spraying, regenerative thermal oxidizer (RTO), activated carbon, and a 25-meter exhaust stack for emissions compliance[143]. - The company’s wastewater discharge includes chemical oxygen demand (COD) at 139 mg/L, significantly below the limit of 500 mg/L, with an annual discharge of 3.121 tons[145]. - The company’s nitrogen oxides emissions are monitored monthly, with a concentration limit of 150 mg/Nm3[145]. - The company has established a solid waste management system, including a hazardous waste storage area and a disposal agreement with a third-party environmental firm[143]. - The company has implemented measures to reduce carbon emissions, although specific details on the effectiveness of these measures were not provided[148]. Shareholder Engagement - The company is committed to maintaining a high level of shareholder engagement, as evidenced by the participation rates in its meetings[109]. - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, ensuring compliance with relevant regulations[103]. - The total shares held by the board members at the end of the reporting period amounted to 53,529,500 shares, with no changes during the period[111]. - The company has not reported any changes in the positions of directors, supervisors, or senior management during the reporting period[111]. - The company has established a limit of 25% for annual share transfers by directors and senior management during their tenure[154]. - The commitments are being fulfilled normally as of the latest report date[154]. Future Outlook - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[157]. - User data indicates an increase in active users by 20% year-over-year, reaching 5 million active users by the end of 2023[157]. - The company has provided a revenue guidance of 1.5 billion RMB for the next fiscal year, expecting a growth rate of approximately 25%[157]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on expanding the product line in the healthcare sector[157]. - The company is investing 100 million RMB in R&D for new technologies aimed at improving product efficiency and user experience[157]. - Market expansion plans include entering two new provinces in China, projected to increase market share by 10%[157]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a budget of 500 million RMB allocated for potential deals[157]. - Future outlook remains positive, with management expressing confidence in achieving a net profit margin of 15% by the end of 2024[157].

湖北共同药业股份有限公司 董事会 2024 年 4 月 24 日 湖北共同药业股份有限公司 董事会对独立董事独立性评估的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等要求，湖北共同药业股份有限公司（以下 简称"公司"）董事会，就公司在任独立董事的独立性情况进行评估并出具如下专 项意见： 经核查独立董事夏成才先生、姬建生先生、杨健先生的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要 股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系，不存在影响独立董事独立性的情况。因此，符合《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等法律、法规、规范性文件及《公司章程》中关于独立董 事的任职资格及独立性的相关要求。 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 122,227,974.51, representing a 2.35% increase compared to CNY 119,423,435.11 in the same period last year[5] - Net profit attributable to shareholders decreased by 11.86% to CNY 3,547,307.04 from CNY 4,024,418.08 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 122,227,974.51, an increase of 2.26% compared to CNY 119,423,435.11 in Q1 2023[17] - Net profit for Q1 2024 was CNY 2,893,085.07, a decrease of 20.83% from CNY 3,651,134.29 in Q1 2023[18] - Total operating costs for Q1 2024 were CNY 122,389,251.15, up from CNY 120,171,920.93, reflecting a rise of 1.83%[17] Cash Flow - The net cash flow from operating activities improved by 57.80%, reaching CNY -24,222,072.61, compared to CNY -57,394,913.52 in the previous year[10] - Operating cash flow for Q1 2024 showed a net outflow of CNY -24,222,072.61, an improvement from CNY -57,394,913.52 in Q1 2023[19] - Cash inflow from operating activities totaled CNY 157,223,568.99, compared to CNY 120,839,809.00 in the previous year, marking an increase of 30.06%[19] - The net cash flow from financing activities surged by 561.08% to CNY 45,285,025.70, compared to CNY 6,850,178.56 in the previous year, reflecting reduced cash outflow for debt repayment[11] - The net cash flow from investing activities for Q1 2024 was -58,131,796.22, compared to -148,163,433.78 in the same period last year[20] - The cash outflow for financing activities totaled 41,714,974.30, compared to 123,527,591.55 in Q1 2023[20] - The cash inflow from borrowing was 87,000,000.00, reflecting a decrease from the previous year's 130,377,770.11[20] Assets and Liabilities - Total assets increased by 1.26% to CNY 2,478,579,378.33 from CNY 2,447,740,699.18 at the end of the previous year[5] - The total liabilities increased from ¥686,405,942.78 to ¥712,125,543.01, indicating a rise of approximately 3.7%[15] - Total liabilities as of March 31, 2024, were CNY 1,451,381,686.72, compared to CNY 1,423,965,109.22 at the end of Q1 2023, an increase of 1.94%[18] - The company’s total current assets amount to ¥772,701,690.45, down from ¥869,731,565.50 at the beginning of the period, representing a decrease of approximately 11.1%[15] - Cash and cash equivalents decreased from ¥181,973,811.45 to ¥116,793,029.53, a decline of about 35.8%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,788[12] - The largest shareholder, Xi Zuobin, holds 31.72% of shares, totaling 36,567,000 shares[12] - The company has no preferred shareholders as of the reporting period[13] Other Financial Metrics - The company reported a significant increase of 2,911.68% in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to CNY 3,464,603.03 compared to CNY 115,039.00 last year[5] - The company’s weighted average return on equity decreased slightly to 0.37% from 0.43% year-on-year[5] - Research and development expenses for Q1 2024 were CNY 9,505,034.39, down from CNY 10,545,515.62, indicating a reduction of 9.85%[18] - The company reported a decrease in sales expenses to CNY 864,906.68 from CNY 868,263.18, a decline of 0.50%[17] - The company’s financial expenses for Q1 2024 were CNY 2,885,024.73, slightly up from CNY 2,868,072.48, indicating a marginal increase of 0.59%[18] Exchange Rate Impact - The company reported a 1346.65% increase in the impact of exchange rate changes on cash and cash equivalents, amounting to CNY 271,084.66[11] - The cash flow impact from exchange rate changes was 271,084.66, compared to 18,738.78 in the previous year[20] - The company reported a significant decrease in cash and cash equivalents year-over-year, indicating potential liquidity challenges[20] Audit Information - The company did not undergo an audit for the Q1 2024 report[21]

一、2023 年度财务报表审计情况 湖北共同药业股份有限公司（以下简称"公司"）2023 年度财务报表已经大信 会计师事务所（特殊普通合伙）审计，出具了标准无保留意见的审计报告。会计师 认为：公司财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了公 司 2023 年 12 月 31 日合并及母公司的财务状况以及 2023 年度合并及母公司的经营 成果和现金流量，公司根据此次审计结果编制了 2023 年度财务决算报告如下： 二、财务状况、经营成果和现金流量情况分析 湖北共同药业股份有限公司 2023 年度财务决算报告 （一）资产情况 应收账款期末较期初增加 21.61%，主要系四季度销售收入增加所致； 应收款项融资期末较期初下降 61.25%，主要系期末在手信用级别较高且尚未到 期的银行承兑票据减少所致； 预付账款期末较期初下降 45.24%，主要系进口原料预付国际信用证减少所致； 其他流动资产期末较期初增加 67.90%，主要系留抵增值税增加所致； 在建工程期末较期初增加 186.82%，主要系子公司新增在建工程所致； 使用权资产期末较期初下降 80.80%，主要系子公司将租赁资产购入转增固定资 产 ...

WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 2024 5-00066 1 22 2206 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 Telephone +86 10 82330558 Fax +86 10 82327668 Internet www.daxincpa.com.cn [2024] 5-00066 2023 12 31 2023 2024 4 24 [2024] 5-00032 2023 8 3101 - 1 - 大信会计师事务所 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP 北京市海淀区知春路 1 号 Room 2206 22/F, Xueyuan International Tower No.1 Zhichun Road, ...

湖北共同药业股份有限公司 审 计 报 告 大信会计师事务所（特殊普通合伙） 大信审字【2024】第 5-00032 号 WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. 大信会计师事务所 北京市海淀区知春路 1 号 学院国际大厦 22 层 2206 邮编 100083 WUYIGE Certified Public Accountants.LLP Room 2206 22/F,Xueyuan International Tower No.1 Zhichun Road,Haidian Dist. Beijing,China,100083 电话 Telephone：+86（10）82330558 传真 Fax： +86（10）82327668 网址 Internet： www.daxincpa.com.cn 审计报告 大信审字[2024]第 5-00032 号 湖北共同药业股份有限公司全体股东： 一、审计意见 我们审计了湖北共同药业股份有限公司（以下简称"贵公司"）的财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及 ...